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the hepatic confluence and when the surrounding bile duct
diameter is large enough to accommodate the device. In the
trial, patients whose unaffected bile duct was less than 6 mm
were excluded to avoid secondary duct injuries and higher
rates of spontaneous stent migration. Additional comparative
safety data for self-expandable metallic stents are needed for
patients who have not undergone a cholecystectomy, which
predominantly applies to those having bile duct strictures in
the setting of chronic pancreatitis. These limitations may
spur development of expandable stents designed to address
these subgroups while minimizing the need for multiple
interventions.
The study’s generalizability is greater than suggested by
Costamagna. Patients who have undergone orthotopic liver
transplantation have the highest risk of a bile duct stricture,
with an annual incidenceof 20%among6500USpatients un-
dergoing transplant, or approximately 1300 cases.1 Approxi-
mately 30000 individuals are diagnosed with chronic pan-
creatitis each year in theUnited States,2 and at least 5% (1500
individuals) are expected to develop a bile duct stricture dur-
ing their illness. These statistics compare with postlaparo-
scopic cholecystectomy, for which the risk of a postoperative
bile duct stricture is approximately 0.05% of 500000 cases
each year, or 2500 incident cases.3
As Costamagna suggests, many postcholecystectomy
strictures occur too close to the hepatic confluence to accom-
modate current self-expandable metallic stent models. Fur-
thermore, some postcholecystectomy strictures result in
intrahepatic or extrahepatic duct transection, which pre-
cludes endoscopic therapy altogether.4
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EarlyAntibiotic Exposure andChildhoodWeightGain
To the Editor Dr Gerber and colleagues assessed the associa-
tion between antibiotic exposure during the first 6months of
life and childhood weight gain and concluded that there was
noassociation.1However, therewas a significant difference in
weight gain in children exposed to any antibiotic in the first
24months of life (P = .001). The subanalyses showed that this
difference was significant in children who received only
1 antibiotic course (P = .01) but was greater in those who re-
ceived 2 courses (P = .02) and even greater in those exposed
to 3 ormore courses (P = .002). Can the authors comment on
these findingsandexplainwhy theydidnot consider these sig-
nificant differences in their discussion?
A number of studies have shown that antibiotic treat-
ment can cause dysbiosis2 and that its effect on weight gain
seems tobeparticularly strong in the first 2 years of life,when
gutmicrobiota is still developing. A recent study of antibiotic
exposurebeforeage2years showed that itwasassociatedwith
an increased riskofobesitybyage4years (odds ratio, 1.21 [95%
CI, 1.07-1.38]) and that the odds ratio increasedwith repeated
exposure.3 The results are similar to those of Gerber and
colleagues,1 but the authors concluded that the administra-
tion of 3 ormore courses of antibiotics before age 2 years was
associatedwith an increased risk of early childhood obesity.3
Gerber and colleagues also observed significant differ-
ences between antibiotic exposure to different drug catego-
ries in the first 2 years of life, but these were greatest in the
case of broad-spectrumantibiotics (P = .004) andmacrolides
(P = .004).1 Use of drugs that are effective against both aero-
bic and anaerobic bacteria, such asmacrolides, has the great-
est effect on increased bodyweight,4 supporting the findings
that changes in antibiotic-related gut microbiota cause dys-
biosis andare associatedwithoverweight.HowdoGerber and
colleagues explain the greater difference in the rate ofweight
gain in children exposed to broad-spectrum antibiotics?
I agree that the primary reasons for limiting antibiotic ex-
posure in young, healthy children include the need to avoid
development of bacterial resistance andantibiotic-related ad-
verseevents.5However, the relationshipsamongantibioticuse,
nutritional parameters, and the characteristics of the micro-
biota are still unclear and require further study.
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In Reply As Dr Esposito points out, growth trajectories did not
differbetweenchildrenexposedvsunexposed toantibiotics in
the first 6 months of life in our study. This primary exposure
windowwasdevelopedapriori basedon thebiologicalmecha-
nism throughwhich antibiotics have been shown to influence
adiposity in animal models. However, because of previous re-
ports citedbyEsposito1,2 (andothers),we also examineda sec-
ondary antibiotic exposure window (24 months) and found a
statistically significant but, in our opinion, clinicallymeaning-
less increase in growth—approximately 150 g over 3 years, the
equivalentofasmall cupofwater.Even if the findingof this sec-
ondary analysis were real, there is no evidence that 150 g of
weight has any untoward health effects for any one individual
and thus shouldnot be considered a larger public health threat
for the population of children exposed to antibiotics. Further-
more,no increase ingrowthwas found in thepreplannedstudy
of twins discordant for antibiotic exposure at 24 months, and
subanalyses revealed no clinically meaningful differences be-
tweenantibiotic spectrum(antianaerobic ormacrolides) or ex-
posure dose response (1, 2, or ≥3 courses).
With respect to Esposito’s comment, conclusions should
not be based solely on P values but instead on point esti-
mates and confidence intervals.3 Large samples (such as this
analysis of 40000patients) can lead to smallPvalues that are
not clinicallymeaningful4 (suchas 150gofweightover 3years’
time). For the results by antibiotic spectrum and number of
courses, the confidence intervals of the various point esti-
mates all overlapped, suggesting that there were no true dif-
ferences across groups.
Esposito also highlights an important distinction be-
tween our study and prior efforts to address this question:
the outcome definition. Scott and colleagues,1 Saari and
colleagues,2 and others have reported associations between
early-life antibiotic use and body mass index using dichoto-
mous outcome definitions to assess obesity over time. The
practice of dichotomizing continuousdata has longbeen con-
demned by statisticians.5 In this case, dichotomizing obesity
suggests that it is an all-or-nothing event and overly simpli-
fies the characterizationof growthover time. For instance, as-
sessing whether a child ever reached the 95th percentile of
bodymass indexwould classify children thatmoved from the
94thpercentile to the95thpercentileasmoving fromnotobese
to obese (1) without following the trajectory of this growth
(eg, assessing if the child subsequently reverted to the 94th
percentile) and (2) ignoringpotentially significantweightgains
or losses that are not proximal to this threshold, such as an in-
crease from the 50th percentile to the 75th percentile. In con-
trast, the analysis of the association between antibiotic expo-
sures and the rate of growth in all children during the first 8
years of life provides amore comprehensive and accurate as-
sessment of antibiotic use and weight gain.
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Laboratory Testing in the Setting of Diabetic
Scleredema
To the Editor Dr Chatterjee, in his case presentation of a pa-
tient with diabetic scleredema,1 did not explain the rationale
for ordering a serum immunofixation. Presumably, it was or-
dered toevaluate thepatient for thepossibilityofmultiplemy-
eloma. However, based on the patient’s presentation and ab-
sence of anemia, renal insufficiency, hyperproteinemia,
hypercalcemia, or osteolytic lesions, plasma cell disorders
shouldnot have beenhighon the list of possible diagnoses.2,3
In addition, if a plasma cell disorder was suspected, a serum
protein electrophoresis studywith serumfree light chain test-
ingwouldhavebeenmoreappropriate,4,5 as those tests incom-
bination have a sensitivity of 100%, specificity of 97%, posi-
tive predictive value of 60%, and a negative predictive value
of 100% for the diagnosis of plasma cell disorder.
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